US4921697A
Expired / Lapsed
US
⏱️ 0.0 years remaining
IFN-gamma as an active substance for inhibiting and preventing degradation processes in bone
Assignee: Boehringer Ingelheim International GmbH
•
Filing: 1986-05-30
•
Granted: 1990-05-01
•
Expires: 2006-05-30
Abstract
Abstract This invention relates to methods for preventing and treating bone diseases caused by bone loss comprising administering to a patient a pharmaceutical composition with IFN-γ as the active substance.
Inventors
- 👤 Meinrad Peterlik
- 👤 Oskar Hoffmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 02:03
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/217; A61P; A61P1/00; A61P1/02; A61P19/00; A61P19/08; A61P19/10; A61P3/00; A61P35/00; A61P43/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
34 words
A method for inhibiting, preventing, or controlling bone loss in a patient comprising administering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control said bone loss.
Claim 2
Independent Claim
34 words
A method for inhibiting, preventing, or controlling bone loss in a patient comprising administering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control said bone loss.
Claim 3
Dependent Claim
22 words
The method of claim 1 wherein said bone loss is a degenerative systemic or local bone loss of inflammatory or non-inflammatory origin.
Claim 4
Dependent Claim
20 words
The method of claim 1 wherein said bone loss is caused by local or generalized decomposition of the bone tissue.
Claim 5
Dependent Claim
14 words
The method of claim 1 wherein said bone loss is caused by pathological disease.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein said bone loss is a result of osteoporosis.
Claim 7
Dependent Claim
15 words
The method of claim 1 wherein said bone loss is a result of Paget's disease.
Claim 8
Dependent Claim
15 words
The method of claim 1 wherein said bone loss is the result of rheumatic arthritis.
Claim 9
Dependent Claim
17 words
The method, of claim 1 wherein said bone loss is the result of jaw and tooth diseases.
Claim 10
Dependent Claim
17 words
The method of claim 1 wherein said bone loss is the result of osteodystophies caused by parathormone.
Claim 11
Dependent Claim
17 words
The method of claim 1 wherein said bone loss is the result of hypercalcaemia in prostaglandinsynthesizing tumors.
Claim 12
Independent Claim
48 words
A method for inhibiting, preventing, or controlling bone loss is a patient comprising adminstering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control bone loss, in combination with calcitonin in an amount sufficient to inhibit, prevent, or control bone loss.
Claim 13
Independent Claim
48 words
A method for inhibiting, preventing, or controlling bone loss is a patient comprising adminstering a pharmaceutical composition to said patient comprising gamma-interferon in an amount effective to inhibit, prevent, or control bone loss, in combination with calcitonin in an amount sufficient to inhibit, prevent, or control bone loss.
References Cited (Backward Citations)
DE3436638A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-30 | 1993-10-30 | 1994-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-30 | 1997-10-30 | 1998-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-30 | 2001-10-30 | 2002-05-01 | $7700.00 | Window Closed / Lapsed |